{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:13:40Z","timestamp":1791324820263,"version":"4.3.1"},"reference-count":96,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T00:00:00Z","timestamp":1518566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T00:00:00Z","timestamp":1518566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1111\/bjd.15831","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T12:27:06Z","timestamp":1500467226000},"page":"640-649","source":"Crossref","is-referenced-by-count":15,"title":["Reporting of outcomes in randomized controlled trials on nail psoriasis: a systematic review"],"prefix":"10.1093","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7074-7060","authenticated-orcid":false,"given":"C.I.","family":"Busard","sequence":"first","affiliation":[{"name":"Department of Dermatology; Academic Medical Center; Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.Y.C.","family":"Nolte","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Academic Medical Center; Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Pasch","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Radboud University Medical Center; Nijmegen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.I.","family":"Spuls","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Academic Medical Center; Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,2,14]]},"reference":[{"key":"10.1111\/bjd.15831-BIB0001|bjd15831-cit-0001","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10227-002-0143-0","article-title":"Psoriatic nails: a prospective clinical study","volume":"7","author":"Salomon","year":"2003","journal-title":"J Cutan Med Surg"},{"key":"10.1111\/bjd.15831-BIB0002|bjd15831-cit-0002","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000360696","article-title":"The impact of fingernail psoriasis on patients\u2019 health-related and disease-specific quality of life","volume":"229","author":"Velden","year":"2014","journal-title":"Dermatology"},{"key":"10.1111\/bjd.15831-BIB0003|bjd15831-cit-0003","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/bjd.12354","article-title":"Nail psoriasis: a questionnaire-based survey","volume":"169","author":"Klaassen","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15831-BIB0004|bjd15831-cit-0004","first-page":"CD007633","article-title":"Interventions for nail psoriasis","author":"Vries","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/bjd.15831-BIB0005|bjd15831-cit-0005","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jaad.2014.02.010","article-title":"Scoring nail psoriasis","volume":"70","author":"Klaassen","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15831-BIB0006|bjd15831-cit-0006","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/rheumatology\/33.9.834","article-title":"Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease","volume":"33","author":"Jones","year":"1994","journal-title":"Br J Rheumatol"},{"key":"10.1111\/bjd.15831-BIB0007|bjd15831-cit-0007","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000018281","article-title":"Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double-blind study","volume":"199","author":"Jong","year":"1999","journal-title":"Dermatology"},{"key":"10.1111\/bjd.15831-BIB0008|bjd15831-cit-0008","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1046\/j.1365-2133.2003.05725.x","article-title":"A nail psoriasis severity index","volume":"150","author":"Baran","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15831-BIB0009|bjd15831-cit-0009","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","article-title":"Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis","volume":"49","author":"Rich","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15831-BIB0010|bjd15831-cit-0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2230.2006.02305.x","article-title":"Interobserver reliability of the Nail Psoriasis Severity Index","volume":"32","author":"Aktan","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/bjd.15831-BIB0011|bjd15831-cit-0011","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jaad.2004.11.044","article-title":"Modification of the nail psoriasis severity index","volume":"53","author":"Parrish","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15831-BIB0012|bjd15831-cit-0012","first-page":"123","article-title":"The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis","volume":"34","author":"Cassell","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1111\/bjd.15831-BIB0013|bjd15831-cit-0013","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3899\/jrheum.140177","article-title":"The Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index (B-SNIPI): a novel index to measure all non-plaque psoriasis subsets","volume":"41","author":"Patel","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1111\/bjd.15831-BIB0014|bjd15831-cit-0014","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bjd.12664","article-title":"Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes","volume":"170","author":"Augustin","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15831-BIB0015|bjd15831-cit-0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1468-3083.2009.03344.x","article-title":"Development and validation of nail psoriasis quality of life scale (NPQ10)","volume":"24","author":"Ortonne","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.15831-BIB0016|bjd15831-cit-0016","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/jid.2014.320","article-title":"The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology","volume":"135","author":"Schmitt","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.15831-BIB0017|bjd15831-cit-0017","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11136-010-9606-8","article-title":"The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study","volume":"19","author":"Mokkink","year":"2010","journal-title":"Qual Life Res"},{"key":"10.1111\/bjd.15831-BIB0018|bjd15831-cit-0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-015-1038-x","article-title":"The COMET initiative database: progress and activities update (2014)","volume":"16","author":"Gargon","year":"2015","journal-title":"Trials"},{"key":"10.1111\/bjd.15831-BIB0019|bjd15831-cit-0019","first-page":"799","article-title":"Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III","volume":"24","author":"Bellamy","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1111\/bjd.15831-BIB0020|bjd15831-cit-0020","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/bjd.14337","article-title":"Report from the kick-off meeting of the Cochrane Skin Group Core Outcome Set Initiative (CSG-COUSIN)","volume":"174","author":"Schmitt","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15831-BIB0021|bjd15831-cit-0021","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s13063-016-1555-2","article-title":"How to select outcome measurement instruments for outcomes included in a \u2018core outcome set\u2019 - a practical guideline","volume":"17","author":"Prinsen","year":"2016","journal-title":"Trials"},{"key":"10.1111\/bjd.15831-BIB0022|bjd15831-cit-0022","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjd.14773","article-title":"Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema\/dermatitis clinical trials (HOME initiative)","volume":"175","author":"Chalmers","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15831-BIB0023|bjd15831-cit-0023","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/pcmr.12354","article-title":"Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus","volume":"28","author":"Eleftheriadou","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1111\/bjd.15831-BIB0024|bjd15831-cit-0024","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/bjd.14588","article-title":"Reporting of symptoms in randomized controlled trials of atopic eczema treatments: a systematic review","volume":"175","author":"Gerbens","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15831-BIB0025|bjd15831-cit-0025","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1365-2133.2012.11056.x","article-title":"Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials","volume":"167","author":"Eleftheriadou","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15831-BIB0026|bjd15831-cit-0026","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3899\/jrheum.170150","article-title":"Defining outcome measures for psoriatic arthritis: a report from the GRAPPA-OMERACT Working Group","volume":"44","author":"Ogdie","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1111\/bjd.15831-BIB0027|bjd15831-cit-0027","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","article-title":"International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials","volume":"76","author":"Orbai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/bjd.15831-BIB0028|bjd15831-cit-0028","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3899\/jrheum.170151","article-title":"Defining outcome measures for psoriasis: the IDEOM report from the GRAPPA 2016 annual meeting","volume":"44","author":"Callis Duffin","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1111\/bjd.15831-BIB0029|bjd15831-cit-0029","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1111\/bjd.15831-BIB0030|bjd15831-cit-0030","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1346-8138.2011.01347.x","article-title":"Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2\/3 clinical trial","volume":"39","author":"Igarashi","year":"2012","journal-title":"J Dermatol"},{"key":"10.1111\/bjd.15831-BIB0031|bjd15831-cit-0031","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1136\/annrheumdis-2013-204902","article-title":"Clinical efficacy, radiographic and safety findings through 5\u00a0years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomized, placebo-controlled trial (the GO-REVEAL study)","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/bjd.15831-BIB0032|bjd15831-cit-0032","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/bjd.12060","article-title":"A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis","volume":"168","author":"Ortonne","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15831-BIB0033|bjd15831-cit-0033","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/bjd.12632","article-title":"Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1","volume":"170","author":"Rich","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15831-BIB0034|bjd15831-cit-0034","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jaad.2007.07.042","article-title":"Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1\u00a0year","volume":"58","author":"Rich","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15831-BIB0035|bjd15831-cit-0035","unstructured":"ClinicalTrials.gov A study of guselkumab in the treatment of participants with moderate to severe plaque-type psoriasis with randomized withdrawal and retreatment (VOYAGE 2) www.clinicaltrials.gov\/show\/NCT02207244"},{"key":"10.1111\/bjd.15831-BIB0036|bjd15831-cit-0036","unstructured":"ClinicalTrials.gov A study of guselkumab in the treatment of participants with moderate to severe plaque-type psoriasis (VOYAGE 1) www.clinicaltrials.gov\/show\/NCT02207231"},{"key":"10.1111\/bjd.15831-BIB0037|bjd15831-cit-0037","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1590\/S0365-05962012000200003","article-title":"Comparison of nail lacquer clobetasol efficacy at 0.05%, 1% and 8% in nail psoriasis treatment: prospective, controlled and randomized pilot study","volume":"87","author":"Nakamura","year":"2012","journal-title":"An Bras Dermatol"},{"key":"10.1111\/bjd.15831-BIB0038|bjd15831-cit-0038","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/jdv.12198","article-title":"Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and\/or feet: post hoc analysis of REACH","volume":"28","author":"Poulin","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.15831-BIB0039|bjd15831-cit-0039","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2010.04.014","article-title":"Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial","volume":"59","author":"Torii","year":"2010","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1111\/bjd.15831-BIB0040|bjd15831-cit-0040","first-page":"279","article-title":"Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis","volume":"88","author":"Tzung","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/bjd.15831-BIB0041|bjd15831-cit-0041","unstructured":"EU Clinical Trials Register A phase IIa, multicentre, randomised, double-blind, parallel group, placebo controlled study to evaluate safety, tolerability and clinical efficacy of MT-1303 in subjects with moderate to severe chronic plaque psoriasis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-005750-27\/EE"},{"key":"10.1111\/bjd.15831-BIB0042|bjd15831-cit-0042","unstructured":"EU Clinical Trials Register An independent prospective randomised controlled trial comparing the efficacy and cost effectiveness of infliximab and etanercept in \u2018high need\u2019 patients with moderate to severe chronic plaque type psoriasis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-007492-24\/NL"},{"key":"10.1111\/bjd.15831-BIB0043|bjd15831-cit-0043","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1468-3083.2012.04642.x","article-title":"Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study","volume":"27","author":"Simone","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.15831-BIB0044|bjd15831-cit-0044","first-page":"185","article-title":"Randomized controlled trial of a water-soluble nail lacquer based on hydroxypropyl-chitosan (HPCH), in the management of nail psoriasis","volume":"7","author":"Cantoresi","year":"2014","journal-title":"Clin Cosmet Invest Dermatol"},{"key":"10.1111\/bjd.15831-BIB0045|bjd15831-cit-0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/bjd.15831-BIB0046|bjd15831-cit-0046","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.phymed.2014.02.013","article-title":"Efficacy and safety of Indigo naturalis extract in oil (Lindioil) in treating nail psoriasis: a randomized, observer-blind, vehicle-controlled trial","volume":"21","author":"Lin","year":"2014","journal-title":"Phytomedicine"},{"key":"10.1111\/bjd.15831-BIB0047|bjd15831-cit-0047","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamadermatol.2014.5460","article-title":"A Chinese herb, Indigo naturalis, extracted in oil (Lindioil) used topically to treat psoriatic nails: a randomized clinical trial","volume":"151","author":"Lin","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1111\/bjd.15831-BIB0048|bjd15831-cit-0048","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/1346-8138.12229","article-title":"Treatment of nail psoriasis with tumor necrosis factor-alpha blocker agents: an open-label, unblinded, comparative study","volume":"40","author":"Ozmen","year":"2013","journal-title":"J Dermatol"},{"key":"10.1111\/bjd.15831-BIB0049|bjd15831-cit-0049","unstructured":"ClinicalTrials.gov Dose response and safety study of topical methotrexate for the treatment of fingernail psoriasis www.clinicaltrials.gov\/show\/NCT00666354"},{"key":"10.1111\/bjd.15831-BIB0050|bjd15831-cit-0050","unstructured":"ClinicalTrials.gov A study to evaluate the safety and efficacy of adalimumab in subjects with chronic plaque psoriasis and nail psoriasis www.clinicaltrials.gov\/show\/NCT02016482"},{"key":"10.1111\/bjd.15831-BIB0051|bjd15831-cit-0051","unstructured":"ClinicalTrials.gov 308nm Excimer laser for treatment of fingernail psoriasis (NAPSI) www.clinicaltrials.gov\/show\/NCT02168933"},{"key":"10.1111\/bjd.15831-BIB0052|bjd15831-cit-0052","unstructured":"ClinicalTrials.gov Efficacy of golimumab in combination with methotrexate (Mtx) versus Mtx monotherapy, in improving dactylitis, in Mtx na\u00efve psoriatic arthritis patients (GO-DACT) www.clinicaltrials.gov\/show\/NCT02065713"},{"key":"10.1111\/bjd.15831-BIB0053|bjd15831-cit-0053","doi-asserted-by":"crossref","DOI":"10.3109\/14764172.2013.854627","article-title":"Clinical trial study in the treatment of nail psoriasis with pulsed dye laser","author":"Goldust","year":"2013","journal-title":"J Cosmet Laser Ther"},{"key":"10.1111\/bjd.15831-BIB0054|bjd15831-cit-0054","unstructured":"ClinicalTrials.gov Study of safety, tolerability, and efficacy of secukinumab in subjects with moderate to severe nail psoriasis (TRANSFIGURE) www.clinicaltrials.gov\/show\/NCT01807520"},{"key":"10.1111\/bjd.15831-BIB0055|bjd15831-cit-0055","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/jdv.12996","article-title":"Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis","volume":"29","author":"Langley","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.15831-BIB0056|bjd15831-cit-0056","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15831-BIB0057|bjd15831-cit-0057","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15831-BIB0058|bjd15831-cit-0058","unstructured":"EU Clinical Trials Register An international prospective, double-blind, placebo-controlled phase III RCT in which patients with moderate to severe psoriasis vulgaris are treated with s.c. methotrexate using an optimized treatment schedule www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-002716-10\/GB"},{"key":"10.1111\/bjd.15831-BIB0059|bjd15831-cit-0059","unstructured":"EU Clinical Trials Register A randomised, double blind, double dummy, active comparator and placebo controlled confirmative non-inferiority trial of FP187 compared to Fumaderm in moderate to severe plaque psoriasis www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-005685-35\/DE"},{"key":"10.1111\/bjd.15831-BIB0060|bjd15831-cit-0060","unstructured":"EU Clinical Trials Register A phase 3, randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of tofacitinib (CP-690,550) in subjects with active psoriatic arthritis and an inadequate response to at least one TNF inhibitor www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-001368-46\/ES"},{"key":"10.1111\/bjd.15831-BIB0061|bjd15831-cit-0061","unstructured":"EU Clinical Trials Register A randomized, double blind, placebo controlled, parallel groups, pilot study to assess the effects of two new nail lacquers, cyclosporine 5% and calcipotriol 0.005%, in the treatment of nail psoriasis - ND www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2010-019706-16-IT"},{"key":"10.1111\/bjd.15831-BIB0062|bjd15831-cit-0062","unstructured":"ISRCTN Registry A study of pre-clinical joint disease in psoriasis and the imaging response to ustekinumab www.isrctn.com\/ISRCTN18043449"},{"key":"10.1111\/bjd.15831-BIB0063|bjd15831-cit-0063","unstructured":"ClinicalTrials.gov A study comparing the safety and efficacy of two dosing regimens of ABT-874 to placebo in subjects with moderate to severe chronic plaque psoriasis www.clinicaltrials.gov\/show\/NCT00570986"},{"key":"10.1111\/bjd.15831-BIB0064|bjd15831-cit-0064","unstructured":"ClinicalTrials.gov Efficacy of alitretinoin treatment in patients with pustular form of psoriasis www.clinicaltrials.gov\/ct2\/show\/NCT01245140"},{"key":"10.1111\/bjd.15831-BIB0065|bjd15831-cit-0065","unstructured":"ClinicalTrials.gov A one-year study to evaluate the efficacy and safety of CP-690,550 for patients with moderate to severe chronic plaque psoriasis www.clinicaltrials.gov\/show\/NCT01309737"},{"key":"10.1111\/bjd.15831-BIB0066|bjd15831-cit-0066","unstructured":"ClinicalTrials.gov Comparison of efficacy of intralesional triamcinolone injection and clobetasol propionate ointment for psoriatic nails www.clinicaltrials.gov\/show\/NCT01703325"},{"key":"10.1111\/bjd.15831-BIB0067|bjd15831-cit-0067","unstructured":"ClinicalTrials.gov Treatment of palmoplantar psoriasis with low doses interferential current www.clinicaltrials.gov\/show\/NCT01765985"},{"key":"10.1111\/bjd.15831-BIB0068|bjd15831-cit-0068","unstructured":"ClinicalTrials.gov Efficacy and safety of namilumab (MT203) for plaque psoriasis www.clinicaltrials.gov\/show\/NCT02129777"},{"key":"10.1111\/bjd.15831-BIB0069|bjd15831-cit-0069","unstructured":"ClinicalTrials.gov Efficacy and safety of tazarotene gel in nail psoriasis www.clinicaltrials.gov\/show\/NCT02235480"},{"key":"10.1111\/bjd.15831-BIB0070|bjd15831-cit-0070","unstructured":"ClinicalTrials.gov An efficacy and safety of CNTO 1959 (guselkumab) in participants with moderate to severe plaque-type psoriasis www.clinicaltrials.gov\/show\/NCT02325219"},{"key":"10.1111\/bjd.15831-BIB0071|bjd15831-cit-0071","unstructured":"ClinicalTrials.gov A study comparing different dosing regimens of ixekizumab (LY2439821) in participants with moderate to severe plaque psoriasis (IXORA-P) www.clinicaltrials.gov\/show\/NCT02513550"},{"key":"10.1111\/bjd.15831-BIB0072|bjd15831-cit-0072","unstructured":"ClinicalTrials.gov A study of ixekizumab (LY2439821) in participants with moderate-to-severe plaque psoriasis (IXORA-S) www.clinicaltrials.gov\/show\/NCT02561806"},{"key":"10.1111\/bjd.15831-BIB0073|bjd15831-cit-0073","unstructured":"ClinicalTrials.gov Study to evaluate the efficacy and safety of P-3073 nail solution in the treatment of nails affected by psoriasis www.clinicaltrials.gov\/show\/NCT02606760"},{"key":"10.1111\/bjd.15831-BIB0074|bjd15831-cit-0074","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/jdv.12359","article-title":"Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial","volume":"28","author":"Paul","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.15831-BIB0075|bjd15831-cit-0075","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/09546639909056030","article-title":"Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation","volume":"10","author":"Baran","year":"1999","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/bjd.15831-BIB0076|bjd15831-cit-0076","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000068469","article-title":"Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study","volume":"206","author":"Cannavo","year":"2003","journal-title":"Dermatology"},{"key":"10.1111\/bjd.15831-BIB0077|bjd15831-cit-0077","first-page":"912","article-title":"A randomized, double-blinded trial evaluating the efficacy and tolerability of vectical ointment (calcitriol 3 mcg\/g ointment) when compared to betamethasone diproprionate ointment (64\u00a0mg\/g) in patients with nail psoriasis","volume":"13","author":"Kole","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.15831-BIB0078|bjd15831-cit-0078","first-page":"80","article-title":"Psoriasis of the nails treated with grenz rays: a double-blind bilateral trial","volume":"69","author":"Lindelof","year":"1989","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/bjd.15831-BIB0079|bjd15831-cit-0079","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0190-9622(95)90189-2","article-title":"Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement","volume":"32","author":"Mahrle","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15831-BIB0080|bjd15831-cit-0080","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2340\/000155557590","article-title":"A therapeutic study of nail psoriasis using electron beams","volume":"75","author":"Kwang","year":"1995","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/bjd.15831-BIB0081|bjd15831-cit-0081","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.15831-BIB0082|bjd15831-cit-0082","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2340\/00015555756569","article-title":"Remission of ordinary psoriasis following a short clearance course of cyclosporin","volume":"75","author":"Levell","year":"1995","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/bjd.15831-BIB0083|bjd15831-cit-0083","unstructured":"World Health Organization Efficacy and safety of 0.1%, 0.5% and 1% TAZAROTENE nail lacquer formulation versus vehicle in nail psoriasis. International, multicenter, double-blind, randomized study of four parallel groups. Dose ranging for Tazarotene nail lacquer http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2004-004825-87-HU"},{"key":"10.1111\/bjd.15831-BIB0084|bjd15831-cit-0084","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/j.1468-3083.2010.03927.x","article-title":"Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study","volume":"25","author":"Gumusel","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.15831-BIB0085|bjd15831-cit-0085","unstructured":"EU Clinical Trials Register A double blind, randomized, placebo controlled, multicenter, dose finding study of oral AEB071 assessing Psoriasis Area and Severity Index (PASI) response as a function of dose and treatment duration (primary outcome) in patients with plaque psoriasis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-007160-19\/IT"},{"key":"10.1111\/bjd.15831-BIB0086|bjd15831-cit-0086","unstructured":"EU Clinical Trials Register Efficacy and safety of 8% clobetasol nail lacquer formulation versus vehicle in nail psoriasis www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2006-006569-18-FR"},{"key":"10.1111\/bjd.15831-BIB0087|bjd15831-cit-0087","first-page":"129","article-title":"Treatment of psoriasic onychodystrophy with a hyaluronic acid product and chondroitin-sulphates","volume":"129","author":"Flori","year":"1994","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1111\/bjd.15831-BIB0088|bjd15831-cit-0088","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2340\/00015555-0195","article-title":"Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study","volume":"87","author":"Rigopoulos","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/bjd.15831-BIB0089|bjd15831-cit-0089","first-page":"355","article-title":"Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study","volume":"68","author":"Scher","year":"2001","journal-title":"Cutis"},{"key":"10.1111\/bjd.15831-BIB0090|bjd15831-cit-0090","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1046\/j.1365-2133.1998.02462.x","article-title":"Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid","volume":"139","author":"Tosti","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15831-BIB0091|bjd15831-cit-0091","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jaad.2011.12.015","article-title":"The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: a randomized, double-blind, intrapatient left-to-right study","volume":"66","author":"Treewittayapoom","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15831-BIB0092|bjd15831-cit-0092","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2340\/0001555572134136","article-title":"A double-blind study of superficial radiotherapy in psoriatic nail dystrophy","volume":"72","author":"Yu","year":"1992","journal-title":"Acta Derm Venereol"},{"issue":"Suppl. 1","key":"10.1111\/bjd.15831-BIB0093|bjd15831-cit-0093","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000316177","article-title":"Methods of outcomes measurement in nail psoriasis","volume":"221","author":"Augustin","year":"2010","journal-title":"Dermatology"},{"key":"10.1111\/bjd.15831-BIB0094|bjd15831-cit-0094","first-page":"1051","article-title":"The agreement among the different ways of measuring NAPSI and their correlation with DLQI","volume":"12","author":"Kyriakou","year":"2014","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1111\/bjd.15831-BIB0095|bjd15831-cit-0095","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaad.2005.11.1064","article-title":"Alefacept treatment of psoriatic nail disease: how severe should nail psoriasis be?","volume":"54","author":"Korver","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15831-BIB0096|bjd15831-cit-0096","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s11136-015-1136-y","article-title":"Patient-relevant needs and treatment goals in nail psoriasis","volume":"25","author":"Blome","year":"2016","journal-title":"Qual Life Res"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.15831","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.15831\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T16:41:03Z","timestamp":1719333663000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/178\/3\/640\/6687376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,14]]},"references-count":96,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.15831","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2,14]]}}}